Actively Recruiting
A Phase 2 Study of WU-CART-007, an Anti-CD7 Allogeneic CAR-T Cell Therapy in T-Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (T-RRex)
Led by Wugen, Inc. · Updated on 2026-05-12
125
Participants Needed
15
Research Sites
204 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The T-RRex study evaluates the efficacy of WU-CART-007 for patients with Relapsed/Refractory (R/R) T-Cell Acute Lymphoblastic Leukemia (T-ALL)/Lymphoblastic Lymphoma (LBL) and to WU-CART-007 as a therapy to induce complete Minimum Residual Disease (MRD) negative response
CONDITIONS
Official Title
A Phase 2 Study of WU-CART-007, an Anti-CD7 Allogeneic CAR-T Cell Therapy in T-Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (T-RRex)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Evidence of T-ALL or T-LBL as defined by WHO, with relapse/refractory disease or MRD positive
- Age 6 months or older
- Adequate organ function
- ECOG performance status 0 or 1, or Karnofsky score 70 or above at screening
You will not qualify if you...
- Prior treatment with any anti-CD7 therapy
- Decompensated hemolytic anemia
- Grade 2 to 4 acute or extensive chronic graft-versus-host disease requiring systemic immunosuppression
- Grade 1 graft-versus-host disease without immunosuppression or Grade 2 skin graft-versus-host disease treated only with topical therapy are allowed
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 15 locations
1
City of Hope
Duarte, California, United States, 91010
Actively Recruiting
2
Children's Hospital Los Angeles
Los Angeles, California, United States, 90027
Actively Recruiting
3
Colorado Blood Cancer Institute
Denver, Colorado, United States, 80218
Actively Recruiting
4
H. Lee Moffitt Cancer Center and Research Institute Hospital
Tampa, Florida, United States, 33612
Actively Recruiting
5
Washington University Saint Louis
St Louis, Missouri, United States, 63108
Actively Recruiting
6
Oncology Hematology Care
Cincinnati, Ohio, United States, 45226
Actively Recruiting
7
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio, United States, 45229
Actively Recruiting
8
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania, United States, 19390
Actively Recruiting
9
TriStar Bone Marrow Transplant / Sarah Cannon Transplant & Cellular Therapy
Nashville, Tennessee, United States, 37203
Actively Recruiting
10
MD Anderson Cancer Center
Houston, Texas, United States, 77030
Actively Recruiting
11
Sarah Cannon Transplant and Cellular Therapy Methodist Hospital
San Antonio, Texas, United States, 78229
Actively Recruiting
12
Sarah Cannon, Virginia Oncology Associates
Norfolk, Virginia, United States, 23502
Actively Recruiting
13
Seattle Children's Hospital
Seattle, Washington, United States, 98105
Actively Recruiting
14
Peter Mac Callum Cancer Institute
Melbourne, Victoria, Australia, 3000
Actively Recruiting
15
Royal Children's Melbourne
Melbourne, Victoria, Australia, 3000
Actively Recruiting
Research Team
W
Wugen Clinical Trials
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here